Mankind Pharma IPO Subscription Status
Mankind Pharma IPO was subscribed 15.32 times when bidding closed on 27 Apr 2023: QIB 49.16x, NII 3.8x, Retail 0.92x.
The Mankind Pharma IPO has been subscribed 15.32x times overall. Retail investors have shown interest with bids for 0.92x the shares available. The Non-Institutional Investor (NII) category has been subscribed 3.8x. Within NII, Big HNI (B-HNI) subscribed 4.99x and Small HNI (S-HNI) subscribed 1.41x. Qualified Institutional Buyers (QIBs) have subscribed 49.16x. Data last updated on 10 Nov, 11:47 AM.
The IPO subscription period has ended. Given the strong demand, the allotment process is expected to be highly competitive. The issue opened on 25 Apr, 2023 and closes on 27 Apr, 2023. The shares are expected to list on stock exchanges on 09 May, 2023.
Researched & reviewed by
Abhishek Vohera,
Founder, IPO Guru
Last updated
Figures sourced from the RHP, BSE & NSE
Live bidding
Shares bid against shares offered, category by category, as published by the exchanges. Summary splits NII into bHNI (above ₹10 lakh) and sHNI (₹2–10 lakh); switch to Detailed for the exchange's own sub-category rows.
| Category | Bid details | Times |
|---|---|---|
| QIB | - of - - | 49.16x |
| NII | - of - - | 3.8x |
bHNI — bid amount above ₹10 Lakh |
- - | 4.99 |
sHNI — bid amount ₹2–10 Lakh |
- - | 1.41 |
| Retail | - of - - | 0.92x |
| TOTAL | - - | 15.32x |
Mankind Pharma IPO allotment probability
Your odds of an allotment in each category at the current subscription.
Odds = allotment slots ÷ applications, or the subscription multiple where counts aren't available. Retail and HNI allotment is by lottery; QIB is proportionate. Not investment advice.
Subscription insights
What the current book is saying, read off the category numbers above.
Retail Allotment
Currently undersubscribed. Retail investors applying now have a high mathematical probability of receiving full allotment.
Institutional Backing
Massive institutional interest with QIBs subscribing 49.16x. This often signals long-term confidence from professional funds.
Day-wise subscription history
End-of-day subscription across the 3-day bidding window. On phones, tap a day for the category split.
| Date | Total | ||
|---|---|---|---|
|
27 Apr 2023
Day 3 |
15.32x | ▼ | |
|
QIB49.16x
BHNI4.99x
SHNI1.41x
Retail0.92x
|
|||
|
26 Apr 2023
Day 2 |
0.87x | ▼ | |
|
QIB1.86x
BHNI1.21x
SHNI0.64x
Retail0.25x
|
|||
|
25 Apr 2023
Day 1 |
0.14x | ▼ | |
|
QIB0.08x
BHNI0.37x
SHNI0.25x
Retail0.1x
|
|||
Mankind Pharma IPO dates
From the bidding window to listing. Today is 11 November.
- Open 25 Apr 2023
- Close 27 Apr 2023
- Allotment 03 May 2023
- Refund/credit 04 May 2023
- Listing 09 May 2023
What does this subscription data mean?
IPO subscription data tells you how much demand exists for the shares being offered, broken down by investor category. Understanding each category helps you gauge the real sentiment behind the numbers:
- 01 QIB (Qualified Institutional Buyers) — includes mutual funds, FIIs, insurance companies, and banks. QIBs do deep due diligence before bidding. A QIB subscription above 10x is a strong institutional endorsement. Watch QIB numbers closely on the final day — they often hold back and flood in after 3 PM.
- 02 NII / HNI (Non-Institutional Investors) — high-net-worth individuals bidding above ₹2 lakh. NII allotment is proportionate (not lottery), so higher NII subscription means smaller per-lot allotment. Big HNI (B-HNI) bids above ₹10 lakh; Small HNI (S-HNI) bids ₹2–10 lakh.
- 03 Retail — individual investors bidding up to ₹2 lakh. When retail is below 1x, everyone who applied gets full allotment. When oversubscribed, SEBI mandates a computerised lottery — only 1 lot per successful applicant regardless of how many lots you apply for.
- 04 Overall Subscription — a blended multiple across all categories. A total subscription above 10x is considered strong; above 50x is exceptional and usually predicts strong listing gains.
Data sourced from BSE/NSE. Subscription numbers are updated during bidding hours (10 AM – 5 PM IST) on active subscription days.
Frequently asked
What is the current subscription status of Mankind Pharma IPO?
As of IPO close date (27 Apr, 2023), the Mankind Pharma IPO is subscribed 15.32x times. Retail category is 0.92x, and NII is 3.8x subscribed.
When is the allotment date for Mankind Pharma IPO?
The allotment for Mankind Pharma IPO is expected to be finalized on 03 May, 2023.
What is the GMP of Mankind Pharma?
The Grey Market Premium (GMP) for Mankind Pharma is currently ₹90, indicating a potential listing gain of 8%.
When will Mankind Pharma IPO list on the stock market?
Mankind Pharma is scheduled to list on BSE and NSE on 09 May, 2023.
What are the chances of getting allotment in Mankind Pharma IPO?
The retail category is currently undersubscribed at 0.92x, which means most applicants are likely to receive full allotment. This is a good window to apply if you haven't already.
What does QIB subscription of 49.16x mean for Mankind Pharma IPO?
Strong — QIBs (mutual funds, FIIs, insurance companies) have subscribed 49.16x, indicating high institutional conviction. Heavy QIB demand is historically one of the strongest predictors of a positive listing.
How to check Mankind Pharma IPO allotment status?
After the allotment date (03 May, 2023), you can check your Mankind Pharma IPO allotment status on IPO Guru's allotment checker, on the BSE/NSE website using your PAN or application number, or through your broker's app.
Explore Mankind Pharma IPO further
Track every stage of this IPO, from subscription to listing.
It has listed — go back to the fundamentals.
Live grey market premium, Kostak and Subject to Sauda, with the day-wise trend.
What brokers and analysts are saying about this issue, in one place.
Check with your PAN whether shares were credited to your demat account.
Subscription moves by the hour. Get it on your phone.
Live GMP alerts, subscription updates and allotment status for every Mainboard and SME issue — fast, free and secure.
Not investment advice. Subscription figures are as published by BSE/NSE and change until bidding closes.
